5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:

Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their se

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the an

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinica

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco

ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Suc

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco

Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to t

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highligh

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the an

- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed al

The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zani

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-drive

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRAN

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRA

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Onc

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across

ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short intere

Wells Fargo analyst Derek Archila initiates coverage on ALX Oncology Holdings (NASDAQ:ALXO) with

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:A

ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept a

ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.37) per share which missed the

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-tar

Piper Sandler analyst Allison Bratzel maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Overwe

ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co

ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with tra

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clini

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.36) per share which beat the an

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expre